Menu
 
Research menu
Jump to menu

Publications:  Dr Gunnel Hallden

Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G(2019). Systemic delivery and SPECT/CT in vivo imaging of <sup>125</sup>I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports vol. 9, (1)
10.1038/s41598-019-49150-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61513
Nattress CB, Halldén G(2018). Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Lett vol. 434, 56-69.
10.1016/j.canlet.2018.07.006
Baker AT, Aguirre-Hernández C, Halldén G, Parker AL(2018). Designer Oncolytic Adenovirus: Coming of Age. Cancers (Basel) vol. 10, (6)
10.3390/cancers10060201
Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G(2018). The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics vol. 17, (2) 575-587.
10.1158/1535-7163.MCT-17-0671
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56038
Aguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu YJ, Halldén G(2018). Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through Bcl-2-dependent attenuation of autophagy. Oncogenesis vol. 7, (1)
10.1038/s41389-017-0020-8
Hallden G (2017). Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenoviruses. vol. 28, is. 8, pp. A6-A6. Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36345
Aguirre-Hernandez C, Millan JS, Hallden G (2016). The adenoviral Ad Delta Delta mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells.
Hernandez CA, Hallden G (2016). The adenoviral AdDD mutant enhances mitoxantrone-induced cell death by promoting apoptosis and attenuating autophagy in prostate cancer cells. HUMAN GENE THERAPY. vol. 27, A5-A6.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16163
Pantelidou C, Cherubini G, Lemoine NR, Halldén G(2016). The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11. Oncotarget vol. 7, (13) 15703-15724.
10.18632/oncotarget.7310
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16702
Pantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H, Hallden G(2016). Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE vol. 38, S58-S58.
Sweeney K, Halldén G(2016). Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virother vol. 5, 45-57.
10.2147/OV.S63047
Pantelidou C, Hallden G (2015). An oncolytic adenovirus (Ad Delta 19K) sensitizes pancreatic cancer cells to cytotoxic drugs by promoting DNA-damage and aberrant mitosis through inactivation of checkpoint mediators. HUMAN GENE THERAPY. vol. 26, A19-A20.
Pantelidou C, Lemoine N, Hallden G (2014). Adenoviruses deleted in the anti-apoptotic E1B19K-gene synergise with DNA-damaging drugs through attenuation of DNA-damage repair responses and checkpoint activation in pancreatic cancer cells. HUMAN GENE THERAPY. vol. 25, A17-A17.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7021
Man YKS, Coughlan L, Pantelidou C, Hallden G (2014). Oncolysis is greatly enhanced by retargeting of replication-selective adenoviral mutants to av beta 6-integrin expressing cancers and in combination with cytotoxic drugs. HUMAN GENE THERAPY. vol. 25, A18-A18.
Mercer EJ, Imrali A, Sharpe K, Hallden G, Lu Y-J (2014). Utilizing a potent and selective nonreplicating adenoviral mutant (Ad5-TV-CU), with gene expression controlled by androgen receptor-dependent activation domains in the TMPRSS2 gene, as a novel prodrug-converting enzyme therapy for prostate cancer. CANCER RESEARCH. vol. 74,
10.1158/1538-7445.AM2014-713
Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G et al.(2013). Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells. Endocr Relat Cancer vol. 20, (5) 633-647.
10.1530/ERC-13-0001
Halldén G, Portella G(2012). Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets vol. 16, (10) 945-958.
10.1517/14728222.2012.712962
Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR et al.(2012). Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models. Hum Gene Ther vol. 23, (9) 1003-1015.
10.1089/hum.2012.046
Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F et al.(2012). Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo. Hum Gene Ther vol. 23, (6) 623-634.
10.1089/hum.2011.120
Sweeney KG, Cheong SC, Lemoine NR, Hallden G(2012). A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells. CANCER RESEARCH vol. 72,
10.1158/1538-7445.AM2012-2712
Maya-Pineda HR, Miranda-Rota E, Lemoine NR, Hallden G(2012). Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cells. CANCER RESEARCH vol. 72,
10.1158/1538-7445.AM2012-2713
Halldén G(2012). Adenoviral gene expression and replication in human tumor explant models. Methods Mol Biol vol. 797, 65-78.
10.1007/978-1-61779-340-0_5
Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR, Halldén G(2012). Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region. PLoS One vol. 7, (10)
10.1371/journal.pone.0046617
https://qmro.qmul.ac.uk/xmlui/handle/123456789/4723
Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR, Halldén G(2011). The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther vol. 18, (12) 1157-1165.
10.1038/gt.2011.141
Sweeney K, Cheong SC, Lemoine N, Hallden G(2011). A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells. HUMAN GENE THERAPY vol. 22, (10) A122-A122.
Maya-Pineda H, Miranda E, Lemoine N, Hallden G(2011). Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cells. HUMAN GENE THERAPY vol. 22, (10) A104-A104.
Pantelidou C, Cherubini G, Lemoine NR, Hallden G(2011). Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K gene. HUMAN GENE THERAPY vol. 22, (10) A119-A120.
Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Halldén G(2011). An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther vol. 18, (10) 734-743.
10.1038/cgt.2011.45
Ingemarsdotter CK, Baird SK, Connell CM, Öberg D, Halldén G, McNeish IA(2010). Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene vol. 29, (45) 6051-6063.
10.1038/onc.2010.335
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12879
Sweeney K, Cheong SC, Lemoine N, Hallden G (2010). A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells. HUMAN GENE THERAPY. vol. 21, 1398-1398.
Ekblad M, Oberg D, Lemoine N, Hallden G (2010). Development of an oncolytic adenovirus expressing the prodrug-converting enzyme CD/UPRT (Ad Delta Delta CU). HUMAN GENE THERAPY. vol. 21, 1473-1473.
Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Halldén G(2010). Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum Gene Ther vol. 21, (10) 1311-1325.
10.1089/hum.2010.019
Cherubini G, Kalllin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine N, Hallden G (2010). Investigating a new potent and selective oncolytic adenovirus (Ad Delta Delta) in combination with chemotherapy. HUMAN GENE THERAPY. vol. 21, 1473-1474.
Ekblad M, Halldén G(2010). Adenovirus-based therapy for prostate cancer. Curr Opin Mol Ther vol. 12, (4) 421-431.
Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR, Halldén G(2010). Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res vol. 16, (2) 541-553.
10.1158/1078-0432.CCR-09-1960
Lee M, Choi S, Halldén G, Yo SJ, Schichnes D, Aponte GW(2009). P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion. Am J Physiol Gastrointest Liver Physiol vol. 297, (4) G641-G654.
10.1152/ajpgi.00191.2009
Hallden G(2009). Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. J BUON vol. 14, S61-S67.
Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA (2009). Critical Role for p21 and p27 in Efficacy of Oncolytic Adenovirus dl922-947 in Ovarian Cancer. MOLECULAR THERAPY. vol. 17, S100-S100.
Adam V, Oberg D, Lemoine N, Hallden G (2009). Prostate Cancer Targeting by Replication-Selective Adenoviral Mutants: Combination Treatments with Phytochemical Drugs. MOLECULAR THERAPY. vol. 17, S320-S320.
Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Halldén G(2009). Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res vol. 15, (5) 1730-1740.
10.1158/1078-0432.CCR-08-2008
Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G, Portella G(2008). Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947. CLIN CANCER RES vol. 14, (20) 6505-6514.
10.1158/1078-0432.CCR-08-0200
Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA (2008). Host cell factors in ovarian cancer influencing efficacy of oncolytic adenovirus dl922-947. HUMAN GENE THERAPY. vol. 19, 1083-1083.
Cheong SC, Oberg D, Nick L, Hallden G (2008). Inhibition of late-stage prostate cancer using adenoviral mutants: Expression of an androgen receptor co-repressor and AR-siRNA. HUMAN GENE THERAPY. vol. 19, 1082-1082.
Adam V, Lemoine N, Hallden G (2008). Prostate cancer targeting by replication-selective adenoviral mutants: combination treatments with phytochemical drugs. HUMAN GENE THERAPY. vol. 19, 1165-1165.
Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V et al.(2008). Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther vol. 19, (9) 873-886.
10.1089/hum.2008.047
Seymour LW, Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V et al.(2008). Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus. Hum Gene Ther
10.1089/hgt.2008.047
Adam VS, Lemoine N, Hallden G (2008). Prostate cancer targeting by replication-selective adenoviral mutants: Combination treatments with phytochemical drugs. HUMAN GENE THERAPY. vol. 19, 419-419.
Cheong SC, Wang Y, Meng J-H, Hill R, Sweeney K, Kirn D, Lemoine NR, Halldén G(2008). E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther vol. 15, (1) 40-50.
10.1038/sj.cgt.7701099
Cheong SC, Lemoine N, Hallden G (2007). Inhibition of androgen receptor signaling pathways in prostate cancer cells by adenoviral vectors expressing Hey1. HUMAN GENE THERAPY. vol. 18, 1004-1004.
Gaballah K, Hills A, Curiel D, Hallden G, Harrison P, Partridge M(2007). Lysis of dysplastic but not normal oral keratinocytes and tissue-engineered epithelia with conditionally replicating adenoviruses. CANCER RES vol. 67, (15) 7284-7294.
10.1158/0008-5472.CAN-06-3834
Radhakrishnan S, Hallden G, Chinegwundoh F, Lemoine N (2007). Synergistic enhancement of prostate cancer cell death by combination therapy of adenovirus and chemotherapy. BJU INTERNATIONAL. vol. 99, 28-28.
Choi S, Lee M, Shiu AL, Yo SJ, Hallden G, Aponte GW(2007). GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells. AM J PHYSIOL-GASTR L vol. 292, (5) G1366-G1375.
10.1152/ajpgi.00516.2006
Gaballah K, Partridge M, Hills A, Curiel D, Hallden G, Harrison P (2007). Lysis of dysplastic but not normal organotypical oral epithelium with conditionally replicating adenoviruses. ORAL ONCOLOGY. vol. 2, 181-181.
Radhakrishnan S, Hallden GK, Chinegwundoh F, Lemoine N (2007). Synergistic enhancement of cell death by combination therapy with adenovirus and chemotherapy. JOURNAL OF UROLOGY. vol. 177, 182-183.
10.1016/S0022-5347(18)30788-2
Liu T-C, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D(2005). Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther vol. 12, (17) 1333-1346.
10.1038/sj.gt.3302555
Wang Y, Xue S-A, Hallden G, Francis J, Yuan M, Griffin BE, Lemoine NR(2005). Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res vol. 65, (4) 1523-1531.
10.1158/0008-5472.CAN-04-3113
Lee M, Hadi M, Halldén G, Aponte GW(2005). Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity. J Biol Chem vol. 280, (1) 125-136.
10.1074/jbc.M408858200
Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D et al.(2005). A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res vol. 11, (1) 351-360.
10.1158/1078-0432.ccr-04-2548
Hu JC, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes C (2004). Combination of a second generation genetically modified herpes simplex virus 1 (HSV1) with paclitaxel in the treatment of breast cancer in vitro. JOURNAL OF CLINICAL ONCOLOGY. vol. 22, 57S-57S.
Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR, Patrick G(2004). Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol vol. 25, (1) 173-178.
Liu T-C, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N, Kirn D(2004). An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther vol. 9, (6) 786-803.
10.1016/j.ymthe.2004.03.017
Hu J, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes R (2004). Combination of a second generation genetically modified herpes simplex virus 1 (HSV 1) with paclitaxel in the treatment of breast cancer in vitro. MOLECULAR THERAPY. vol. 9, S105-S105.
Hallden GK, Meng JH, Hill R, Wang YH, Francis J, Lemoine NN, Kirn DH (2004). Combination therapy with adenovirus (Ad5) and cytotoxic drugs can act synergistically to induce cell death in carcinoma cell lines in culture. MOLECULAR THERAPY. vol. 9, S113-S113.
Liu TC, Wang YH, Hallden G, Francis J, Brooks G, Lemoine N, Kirn D (2004). Oncolytic adenovirus E1B-19kD deletion and E3B retention results in both enhanced potency and tumor necrosis factor-mediated selectivity. MOLECULAR THERAPY. vol. 9, S109-S109.
Hill RJ, Hallden GK, Wang YH, Francis J, Simpson C, Kirn DH, Lemoine NR (2004). The gene expression and function of adenoviral E3-genes in murine tumour cell lines. MOLECULAR THERAPY. vol. 9, S374-S375.
Wang YH, Xue SA, Hallden G, Francis J, Griffin BE, Lemoine NR (2004). VAI deleted adenovirus as an oncolytic agent targeting human EBV-associated tumours. MOLECULAR THERAPY. vol. 9, S230-S230.
Halldén G, Thorne SH, Yang J, Kirn DH(2004). Replication-selective oncolytic adenoviruses. Methods Mol Med vol. 90, 71-90.
10.1385/1-59259-429-8:71
Wang Y, Hallden G, Hill R, Anand A, Liu T-C, Francis J, Brooks G, Lemoine N et al.(2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol vol. 21, (11) 1328-1335.
10.1038/nbt887
Halldén G, Hill R, Wang Y, Anand A, Liu T-C, Lemoine NR, Francis J, Hawkins L et al.(2003). Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther vol. 8, (3) 412-424.
10.1016/s1525-0016(03)00199-0
Liu TC, Wang YH, Hallden G, Anand A, Lemoine NR, Kirn DH (2003). Adenoviral E1B-19kD deletion results in enhanced oncolytic effect and reduced toxicity in an immunocompetent murine tumor. MOLECULAR THERAPY. vol. 7, S416-S416.
Hill RJ, Hallden GK, Lemoine NR, Kirn DH (2003). In vitro screening of murine carcinoma cell lines for testing of replication-competent oncolytic adenoviruses. MOLECULAR THERAPY. vol. 7, S362-S362.
Liu TC, Hallden G, Anand A, Wang YH, Lemoine N, Kirn D (2003). Adenovirus E1B-19kD gene deletion enhances oncolytic virus efficacy and selectivity. CANCER GENE THERAPY. vol. 10, S20-S20.
Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ(2002). The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med vol. 8, (4 Suppl) S68-S73.
10.1016/s1471-4914(02)02318-3
Return to top